Sorry you did all that work, I am not disputing th
Post# of 22465
(Total Views: 335)
Posted On: 05/06/2021 5:40:28 AM
Sorry you did all that work, I am not disputing this article you quoted - 8 contracts, 3.2 Billion Pounds.
I also have the problem figuring out what part of that comes to QMC/QMCH. I listed possible income streams, and also the IP of building a complete healthcare ecosystem and strategies for it.
I used the iceberg analogy a while back, in that we know the UK business but not any results for the 20 countries Innova does business in, and whether more countries have been added, or how much more sales for those locations. Innova is a private entity and doesn't make public financial reports. There could be much more sales and those sales are usually in the hundreds of millions to countries.
Looking at Pasaca Capital, their forte does not seem to be the inner workings of companies and business generation, it seems to be the macro-business strategy, connections and finance - they're VC.
We have to remember that in addition to getting QMC uplisted and someday spinning off QMC HealthID, Pasaca Capital also wants to IPO Innova. The better each does, the better the other does. With Pasaca set to own 51 percent of QMC, that makes Innova's future IPO stronger if QMC has high income.
And I also think both parties are getting a heck of a deal because they each have what the other lacks and together the are whole. All the QMC team and business advisors are new within the last two years and basically contribute fleshing out the plan, the strategy for partnerships, building and blitzscaling the ecosystem, and how to put the plan into action. I am sure they were integral to working on the agreement.
Pasaca has the international contacts to bring QMC business in the Pharma supply chain, Biotech clinical trials and authentication and anticounterfeiting areas, at the least, which are huge markets.
Whenever they made the quote about expecting modest revenue at first, well, they've had another 2 5 Billion Pounds of UK business since then, not to mention other possible countries and international businesses. Honestly, I think it's Squires. underpromising and overdelivering, whenever that quote was dated. The numbers have surely increased since then.
All the above is without counting possible future business from the US, which is about 5 times bigger than the UK.
That's why I think Squires made a deal with Pasaca which recognizes the true value of the contributions of QMC, and is fair. IMO.
Everyone,
My posts is of my opinion only. Please conduct your own Due Diligence; this is YOUR investment.
I also have the problem figuring out what part of that comes to QMC/QMCH. I listed possible income streams, and also the IP of building a complete healthcare ecosystem and strategies for it.
I used the iceberg analogy a while back, in that we know the UK business but not any results for the 20 countries Innova does business in, and whether more countries have been added, or how much more sales for those locations. Innova is a private entity and doesn't make public financial reports. There could be much more sales and those sales are usually in the hundreds of millions to countries.
Looking at Pasaca Capital, their forte does not seem to be the inner workings of companies and business generation, it seems to be the macro-business strategy, connections and finance - they're VC.
We have to remember that in addition to getting QMC uplisted and someday spinning off QMC HealthID, Pasaca Capital also wants to IPO Innova. The better each does, the better the other does. With Pasaca set to own 51 percent of QMC, that makes Innova's future IPO stronger if QMC has high income.
And I also think both parties are getting a heck of a deal because they each have what the other lacks and together the are whole. All the QMC team and business advisors are new within the last two years and basically contribute fleshing out the plan, the strategy for partnerships, building and blitzscaling the ecosystem, and how to put the plan into action. I am sure they were integral to working on the agreement.
Pasaca has the international contacts to bring QMC business in the Pharma supply chain, Biotech clinical trials and authentication and anticounterfeiting areas, at the least, which are huge markets.
Whenever they made the quote about expecting modest revenue at first, well, they've had another 2 5 Billion Pounds of UK business since then, not to mention other possible countries and international businesses. Honestly, I think it's Squires. underpromising and overdelivering, whenever that quote was dated. The numbers have surely increased since then.
All the above is without counting possible future business from the US, which is about 5 times bigger than the UK.
That's why I think Squires made a deal with Pasaca which recognizes the true value of the contributions of QMC, and is fair. IMO.
Everyone,
My posts is of my opinion only. Please conduct your own Due Diligence; this is YOUR investment.
(2)
(0)